266 related articles for article (PubMed ID: 23736260)
1. Wnt/β-catenin signalling induces MLL to create epigenetic changes in salivary gland tumours.
Wend P; Fang L; Zhu Q; Schipper JH; Loddenkemper C; Kosel F; Brinkmann V; Eckert K; Hindersin S; Holland JD; Lehr S; Kahn M; Ziebold U; Birchmeier W
EMBO J; 2013 Jul; 32(14):1977-89. PubMed ID: 23736260
[TBL] [Abstract][Full Text] [Related]
2. The Wnt-Driven Mll1 Epigenome Regulates Salivary Gland and Head and Neck Cancer.
Zhu Q; Fang L; Heuberger J; Kranz A; Schipper J; Scheckenbach K; Vidal RO; Sunaga-Franze DY; Müller M; Wulf-Goldenberg A; Sauer S; Birchmeier W
Cell Rep; 2019 Jan; 26(2):415-428.e5. PubMed ID: 30625324
[TBL] [Abstract][Full Text] [Related]
3. Functional and genomic analyses reveal therapeutic potential of targeting β-catenin/CBP activity in head and neck cancer.
Kartha VK; Alamoud KA; Sadykov K; Nguyen BC; Laroche F; Feng H; Lee J; Pai SI; Varelas X; Egloff AM; Snyder-Cappione JE; Belkina AC; Bais MV; Monti S; Kukuruzinska MA
Genome Med; 2018 Jul; 10(1):54. PubMed ID: 30029671
[TBL] [Abstract][Full Text] [Related]
4. Small-molecule inhibition of CBP/catenin interactions eliminates drug-resistant clones in acute lymphoblastic leukemia.
Gang EJ; Hsieh YT; Pham J; Zhao Y; Nguyen C; Huantes S; Park E; Naing K; Klemm L; Swaminathan S; Conway EM; Pelus LM; Crispino J; Mullighan CG; McMillan M; Müschen M; Kahn M; Kim YM
Oncogene; 2014 Apr; 33(17):2169-78. PubMed ID: 23728349
[TBL] [Abstract][Full Text] [Related]
5. Break the loop, escape the cycle?
van Amerongen R; Berns A
EMBO J; 2013 Jul; 32(14):1967-9. PubMed ID: 23749211
[TBL] [Abstract][Full Text] [Related]
6. The β-catenin/CBP-antagonist ICG-001 inhibits pediatric glioma tumorigenicity in a Wnt-independent manner.
Wiese M; Walther N; Diederichs C; Schill F; Monecke S; Salinas G; Sturm D; Pfister SM; Dressel R; Johnsen SA; Kramm CM
Oncotarget; 2017 Apr; 8(16):27300-27313. PubMed ID: 28460484
[TBL] [Abstract][Full Text] [Related]
7. The epigenetic regulator Mll1 is required for Wnt-driven intestinal tumorigenesis and cancer stemness.
Grinat J; Heuberger J; Vidal RO; Goveas N; Kosel F; Berenguer-Llergo A; Kranz A; Wulf-Goldenberg A; Behrens D; Melcher B; Sauer S; Vieth M; Batlle E; Stewart AF; Birchmeier W
Nat Commun; 2020 Dec; 11(1):6422. PubMed ID: 33349639
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of CREB binding protein-beta-catenin signaling down regulates CD133 expression and activates PP2A-PTEN signaling in tumor initiating liver cancer cells.
Tang Y; Berlind J; Mavila N
Cell Commun Signal; 2018 Mar; 16(1):9. PubMed ID: 29530069
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of the Wnt/β-catenin signaling pathway improves the anti-tumor effects of sorafenib against hepatocellular carcinoma.
Lin HH; Feng WC; Lu LC; Shao YY; Hsu CH; Cheng AL
Cancer Lett; 2016 Oct; 381(1):58-66. PubMed ID: 27431312
[TBL] [Abstract][Full Text] [Related]
10. β-Catenin Cooperates with CREB Binding Protein to Promote the Growth of Tumor Cells.
Yu W; Li L; Zheng F; Yang W; Zhao S; Tian C; Yin W; Chen Y; Guo W; Zou L; Deng W
Cell Physiol Biochem; 2017; 44(2):467-478. PubMed ID: 29141249
[TBL] [Abstract][Full Text] [Related]
11. Specific inhibition of CBP/beta-catenin interaction rescues defects in neuronal differentiation caused by a presenilin-1 mutation.
Teo JL; Ma H; Nguyen C; Lam C; Kahn M
Proc Natl Acad Sci U S A; 2005 Aug; 102(34):12171-6. PubMed ID: 16093313
[TBL] [Abstract][Full Text] [Related]
12. β-Catenin/CBP inhibition alters epidermal growth factor receptor fucosylation status in oral squamous cell carcinoma.
Chandler KB; Alamoud KA; Stahl VL; Nguyen BC; Kartha VK; Bais MV; Nomoto K; Owa T; Monti S; Kukuruzinska MA; Costello CE
Mol Omics; 2020 Jun; 16(3):195-209. PubMed ID: 32203567
[TBL] [Abstract][Full Text] [Related]
13. Wnt/β-catenin signalling maintains self-renewal and tumourigenicity of head and neck squamous cell carcinoma stem-like cells by activating Oct4.
Lee SH; Koo BS; Kim JM; Huang S; Rho YS; Bae WJ; Kang HJ; Kim YS; Moon JH; Lim YC
J Pathol; 2014 Sep; 234(1):99-107. PubMed ID: 24871033
[TBL] [Abstract][Full Text] [Related]
14. KDM3 epigenetically controls tumorigenic potentials of human colorectal cancer stem cells through Wnt/β-catenin signalling.
Li J; Yu B; Deng P; Cheng Y; Yu Y; Kevork K; Ramadoss S; Ding X; Li X; Wang CY
Nat Commun; 2017 Apr; 8():15146. PubMed ID: 28440295
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of canonical WNT signaling pathway by β-catenin/CBP inhibitor ICG-001 ameliorates liver fibrosis in vivo through suppression of stromal CXCL12.
Akcora BÖ; Storm G; Bansal R
Biochim Biophys Acta Mol Basis Dis; 2018 Mar; 1864(3):804-818. PubMed ID: 29217140
[TBL] [Abstract][Full Text] [Related]
16. Characterization of Imatinib Resistant CML Leukemic Stem/Initiating Cells and Their Sensitivity to CBP/Catenin Antagonists.
Zhao Y; Wu K; Wu Y; Melendez E; Smbatyan G; Massiello D; Kahn M
Curr Mol Pharmacol; 2018; 11(2):113-121. PubMed ID: 28933312
[TBL] [Abstract][Full Text] [Related]
17. Sam68 Allows Selective Targeting of Human Cancer Stem Cells.
Benoit YD; Mitchell RR; Risueño RM; Orlando L; Tanasijevic B; Boyd AL; Aslostovar L; Salci KR; Shapovalova Z; Russell J; Eguchi M; Golubeva D; Graham M; Xenocostas A; Trus MR; Foley R; Leber B; Collins TJ; Bhatia M
Cell Chem Biol; 2017 Jul; 24(7):833-844.e9. PubMed ID: 28648376
[TBL] [Abstract][Full Text] [Related]
18. The CREB-binding protein inhibitor ICG-001 suppresses pancreatic cancer growth.
Arensman MD; Telesca D; Lay AR; Kershaw KM; Wu N; Donahue TR; Dawson DW
Mol Cancer Ther; 2014 Oct; 13(10):2303-14. PubMed ID: 25082960
[TBL] [Abstract][Full Text] [Related]
19. ICG-001 suppresses growth of gastric cancer cells and reduces chemoresistance of cancer stem cell-like population.
Liu Y; Chen H; Zheng P; Zheng Y; Luo Q; Xie G; Ma Y; Shen L
J Exp Clin Cancer Res; 2017 Sep; 36(1):125. PubMed ID: 28893318
[TBL] [Abstract][Full Text] [Related]
20. Effect of inhibition of CBP-coactivated β-catenin-mediated Wnt signalling in uremic rats with vascular calcifications.
Gravesen E; Nordholm A; Mace M; Morevati M; Høgdall E; Nielsen C; Kjær A; Olgaard K; Lewin E
PLoS One; 2018; 13(8):e0201936. PubMed ID: 30075015
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
